AbbVie, which paid $350 million to license a long-acting amylin analog from the firm Gubra, also recently announced Phase 1 data
By targeting both GLP-1 and GIP receptors, tirzepatide can help people manage their diabetes and lose weight in a way that is more comprehensive than medications that only target one receptor
Niacinamide 5%: Lm m nm, tn nhang, se kht l chn lng, phc hi hng ro bo v da
These include inflammation of the pancreas (pancreatitis), dehydration from a loss of fluids that can lead to kidney problems, low blood sugar with certain diabetes medications, gallbladder problems, and severe stomach problems like gastroparesis
March 10, 2025: Patients transitioning from compounded diabetes / weight loss injections: Stick to licensed sources
The preservation of lean muscle mass during GLP-1-induced weight loss is one of the most important determinants of long-term outcomes and it requires deliberate, structured resistance training alongside the medication